[{"id":"cc90b421-9392-40ee-ba43-05c6880719cc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03206073","created_at":"2021-01-18T15:48:11.018Z","updated_at":"2024-07-02T16:35:32.012Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer","source_id_and_acronym":"NCT03206073","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Vectibix (panitumumab) • Imjudo (tremelimumab-actl) • Pexa-Vec (pexastimogene devacirepvec)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 12/07/2017","start_date":" 12/07/2017","primary_txt":" Primary completion: 09/24/2020","primary_completion_date":" 09/24/2020","study_txt":" Completion: 06/30/2022","study_completion_date":" 06/30/2022","last_update_posted":"2023-10-24"},{"id":"11179753-861b-4698-95e1-75dc7ec8aaaa","acronym":"METROmaJX","url":"https://clinicaltrials.gov/study/NCT02630368","created_at":"2021-01-18T12:47:25.773Z","updated_at":"2025-02-25T16:15:31.717Z","phase":"Phase 1/2","brief_title":"A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX)","source_id_and_acronym":"NCT02630368 - METROmaJX","lead_sponsor":"Institut Bergonié","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • cyclophosphamide • Pexa-Vec (pexastimogene devacirepvec) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 197","initiation":"Initiation: 09/18/2015","start_date":" 09/18/2015","primary_txt":" Primary completion: 05/01/2023","primary_completion_date":" 05/01/2023","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2022-02-02"},{"id":"ff707ef8-060e-474b-a559-9dbdfbdf688b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01394939","created_at":"2021-01-18T05:43:45.759Z","updated_at":"2024-07-02T16:36:36.446Z","phase":"Phase 1/2","brief_title":"Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma","source_id_and_acronym":"NCT01394939","lead_sponsor":"Jennerex Biotherapeutics","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS wild-type • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • Pexa-Vec (pexastimogene devacirepvec)"],"overall_status":"Completed","enrollment":" Enrollment 52","initiation":"Initiation: 01/01/2012","start_date":" 01/01/2012","primary_txt":" Primary completion: 06/01/2015","primary_completion_date":" 06/01/2015","study_txt":" Completion: 10/01/2015","study_completion_date":" 10/01/2015","last_update_posted":"2021-01-08"},{"id":"62baa3b1-251d-4248-8d27-8479e939d9d7","acronym":"PHOCUS","url":"https://clinicaltrials.gov/study/NCT02562755","created_at":"2021-07-05T16:46:12.243Z","updated_at":"2024-07-02T16:36:37.324Z","phase":"Phase 3","brief_title":"Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone","source_id_and_acronym":"NCT02562755 - PHOCUS","lead_sponsor":"SillaJen, Inc.","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • Pexa-Vec (pexastimogene devacirepvec)"],"overall_status":"Completed","enrollment":" Enrollment 459","initiation":"Initiation: 10/01/2015","start_date":" 10/01/2015","primary_txt":" Primary completion: 07/01/2020","primary_completion_date":" 07/01/2020","study_txt":" Completion: 07/01/2020","study_completion_date":" 07/01/2020","last_update_posted":"2020-12-16"}]